eFFECTOR Therapeutics, Inc. (EFTR)
OTCMKTS: EFTR · Delayed Price · USD
0.0460
-0.0005 (-1.08%)
Jul 26, 2024, 3:52 PM EDT - Market closed
eFFECTOR Therapeutics Revenue
Revenue (ttm)
$162.00K
Revenue Growth
-95.44%
P/S Ratio
1.34
Revenue / Employee
$11,571
Employees
14
Market Cap
216.40K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 3.55M | 2.12M | 148.46% |
Dec 31, 2021 | 1.43M | -40.57M | -96.60% |
Dec 31, 2020 | 42.00M | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
EFTR News
- 4 weeks ago - eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq - GlobeNewsWire
- 2 months ago - eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewsWire
- 2 months ago - eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - eFFECTOR Therapeutics to Participate in Upcoming Investor Conference - GlobeNewsWire
- 4 months ago - eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer - GlobeNewsWire
- 4 months ago - eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 months ago - eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire